Daniela Bota
0000-0002-9680-9060
University of California Irvine
224 papers found
Refreshing results…
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons
A Novel Rat Ovarian Cancer Model Developed to Examine Chemotherapy-Related Cognitive Impairments
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy
Atim-42. Double-Blinded, Placebo Controlled Phase 2 Study of Erc1671 in Recurrent Glioblastoma: Os Correlations With Initial and Maximum Cd4+t Lymphocyte Count in the Peripheral Blood
Atim-28. Phase Ii Trial of Av-Gbm-1 (Autologous Dendritic Cells Loaded With Tumor Associated Antigens) as Adjunctive Therapy Following Surgery Plus Concurrent Chemoradiation in Newly Diagnosed Gbm Patients
Rare-36. Bortezomib Woke Up a Patient With Anti-Nmda Receptor Encephalitis Refractory to Standard Therapy and Long Term Follow-Up
European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects
Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain
Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR(octreotide) for Treatment of Recurrent and/or Refractory Meningiomas
Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Ther-06. Proteasome Inhibition in Primary Medulloblastoma Cell Culture and Patient-Derived Xenograft Models: A Potential Therapeutic Implication
Magmas inhibition as a potential treatment strategy in malignant glioma
Magmas inhibition as a potential treatment strategy imalignant glioma
Longitudinal Resting-State Functional Connectivity Confirms Marizomib (Mrz) Crosses the Blood Brain Barrier (Bbb) and Correlates With Hallucination Severity in Recurrent GBM Patients
Safety and Adverse Event Profile of Tumor Treating Fields in Anaplastic Glioma a Post-Marketing Surveillance Analysis
Phase 2 Study of Erc1671 Plus Bevacizumab vs Bevacizumab Plus Placebo in Recurrent GBM Interim Results and Correlations With Cd4+t Lymphocyte Counts
Missing publications? Search for publications with a matching author name.